JG
NKGN

Jefferies Group’s NKGen Biotech, Inc. Common Stock NKGN Stock Holding History

Jefferies Group’s Portfolio NKGN Stock Details NKGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-175,000
Closed -$1.7M – 2064
2021
Q3 		$1.7M Buy
+175,000
New +$1.71M 0.01% 809

Other funds holding NKGN

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
RCM
Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.33B AUM 1.18% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return
KC
Kepos Capital New York $61.3M AUM 12.13% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
FTCM
Fir Tree Capital Management New York $21.8M AUM 1.61% 1-Year Est. Return
SCC
Spring Creek Capital Wichita, Kansas $2.53B AUM 19.59% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Jefferies Group's NKGN Position: Q4 2021 in Review

Jefferies Group sold out of NKGen Biotech, Inc. Common Stock (NKGN) in Q4 2021, closing a stake of 175,000 shares — an estimated $1.7M sold.

Jefferies Group first reported a position in NKGN in Q3 2021 and held it in 1 quarter. The position peaked at $1.7M in Q3 2021. 41 funds tracked by Wall St. Rank hold NKGN as of Q4 2021.

  • Jefferies Group reported no remaining NKGen Biotech, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • Jefferies Group sold 175,000 NKGen Biotech, Inc. Common Stock shares in Q4 2021, an estimated $1.7M.
  • Jefferies Group first reported a position in NKGen Biotech, Inc. Common Stock in Q3 2021 and held it in 1 quarter.
  • Jefferies Group's NKGen Biotech, Inc. Common Stock position peaked at $1.7M in Q3 2021.
  • 41 funds tracked by Wall St. Rank held NKGen Biotech, Inc. Common Stock as of Q4 2021.

Based on Jefferies Group's 13F filing for Q4 2021, filed 14 Feb 2022.